^
    16d
    SCHEMBL4796824: a multifaceted antitumor agent targeting microtubule dynamics, DNA damage, and Wnt/β-catenin signaling in ovarian cancer cells. (PubMed, J Ovarian Res)
    SCHEMBL4796824, a BPR0L075 derivative with antitumor properties, targets tubulin's colchicine binding site and induces DNA damage response in ovarian cancer...Notably, these effects were more pronounced in c-MYC amplified SK-OV-3 cells. In summary, SCHEMBL4796824 disrupts the canonical Wnt/β-catenin signaling, inducing DNA damage, and inhibits the Wnt/β-catenin/c-MYC axis, triggering cellular senescence in a pathway-dependent manner, hinting at a novel therapeutic approach.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CHEK2 (Checkpoint kinase 2)
    |
    SB01
    22d
    Furosemide-Digoxin vs. Polidocanol for Cutaneous Warts (clinicaltrials.gov)
    P2, N=64, Completed, Benha University
    New P2 trial • Head-to-Head
    2ms
    Efficacy of Skin Cooling in Reducing Pain Associated With Non-invasive Treatments of Neurofibromatosis Type 1 Cutaneous Neurofibromas (clinicaltrials.gov)
    P1, N=13, Completed, Massachusetts General Hospital | Recruiting --> Completed | N=30 --> 13 | Trial completion date: Oct 2024 --> Jul 2025 | Trial primary completion date: Oct 2024 --> Jul 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    5ms
    BAP1 as a predictive biomarker of therapeutic response to oncolytic vaccinia virus for metastatic renal cell carcinoma therapy. (PubMed, Cancer Immunol Immunother)
    We identified BAP1 as a potential predictive biomarker for JX-594 treatment and explored its underlying mechanisms. However, given that the study used immunodeficient models, the findings reflect tumor-intrinsic interferon responses and require further validation in immunocompetent models to assess immune microenvironment modulation and clinical relevance.
    Journal
    |
    BAP1 (BRCA1 Associated Protein 1) • IFNB1 (Interferon Beta 1) • IRF7 (Interferon Regulatory Factor 7)
    |
    Pexa-Vec (pexastimogene devacirepvec)
    6ms
    Treatment of Tumors in the Urinary Collecting System of the Kidney or Ureter Using a Light Activated Drug (WST11) (clinicaltrials.gov)
    P1, N=30, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Jul 2025 | Trial primary completion date: Dec 2025 --> Jul 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    Tookad (padeliporfin)
    8ms
    CYT997 Induces Apoptosis in Hypertrophic Scar Fibroblasts and Inhibits Scar Formation. (PubMed, Eur J Pharmacol)
    It also regulated apoptosis-related proteins poly(ADP-ribose) polymerase (PARP) and caspase-3 in HSFs. These findings suggest that CYT997 has potential as a targeted therapy for hypertrophic scars by inducing apoptosis in HSFs and reducing fibrotic activity.
    Journal • PARP Biomarker
    |
    CASP3 (Caspase 3)
    |
    lexibulin (CYT997)
    9ms
    A Trial of a New Type of Photodynamic Therapy (VTP) in the Treatment of Patients With Cancer of the Esophagus Who Have Trouble Swallowing (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Feb 2025 --> Feb 2026 | Trial primary completion date: Feb 2025 --> Feb 2026
    Trial completion date • Trial primary completion date
    |
    Tookad (padeliporfin)
    9ms
    Exploratory Evaluation of [11C]MPC6827 (clinicaltrials.gov)
    P1, N=17, Completed, Columbia University | Recruiting --> Completed | N=40 --> 17 | Trial completion date: Sep 2025 --> Jun 2024
    Trial completion • Enrollment change • Trial completion date
    11ms
    Selectivity and anti-tumor immune elevation by vascular-targeted photodynamic therapy of mouse orthotopic bladder cancer model. (PubMed, Photochem Photobiol)
    Vascular-targeted photodynamic therapy (VTP) with WST11 is a non-surgical tumor ablation approach that is currently being tested in a phase 3 clinical trial for the treatment of upper tract urothelial cancer...Moreover, VTP therapy prolonged the survival of mice bearing orthotopic tumors compared with the untreated control. These results suggest that VTP can selectively ablate malignant tumors in the bladder and promote a robust anti-tumor response in a mouse model that can further augment the therapeutic outcome.
    Preclinical • Journal
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • ITGAM (Integrin, alpha M)
    |
    Tookad (padeliporfin)
    11ms
    Dosing and Tolerability of Deoxycholic Acid Vs. Polidocanol in the Treatment of Neurofibromatosis Type 1 Cutaneous Neurofibromas (clinicaltrials.gov)
    P1, N=20, Completed, Massachusetts General Hospital | Recruiting --> Completed | Trial completion date: Sep 2024 --> Jan 2025 | Trial primary completion date: Apr 2024 --> Jan 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    NF1 (Neurofibromin 1)
    12ms
    ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study (clinicaltrials.gov)
    P3, N=100, Recruiting, Steba Biotech S.A. | Trial primary completion date: Dec 2024 --> Jun 2025
    Trial primary completion date
    |
    Tookad (padeliporfin)
    12ms
    The Efficacy of Percutaneous Renal Puncture Injection of Group A Streptococcal Sclerosant in the Treatment of Simple Renal Cysts (ChiCTR2400095005)
    P=N/A, N=180, The First Affiliated Hospital of Jinan University (Guangzhou Overseas Chinese Hospital); The First Affiliated Hospital of Jinan University (Guangzhou
    New trial